Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression , Amplification, or Mutation
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Trastuzumab rezetecan (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 11 Jun 2024 Planned End Date changed from 30 Jan 2024 to 1 Jun 2025.
- 11 Jun 2024 Planned primary completion date changed from 1 May 2023 to 1 Jun 2025.
- 11 Jun 2024 Status changed from recruiting to active, no longer recruiting.